Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in renal transplant rejection
NCT00695097Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2004
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in renal transplant rejection (RTR) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Biopsy Cell Densities From Baseline to Follow-up at 1 year. Started Aug 2004; status: completed.
02
Drugs
rituximab
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT00695097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695097.